Literature DB >> 788991

N-desmethyldiazepam: a new metabolite of chlordiazepoxide in man.

R Dixon, M A Brooks, E Postma, M R Hackman, S Spector, J D Moore, M A Schwartz.   

Abstract

Following administration of chlordiazepoxide HCl to man, N-desmethyldiazepam, a known metabolite of diazepam (Valium), was identified in plasma. The metabolite was identified on the basis of its thin-layer chromatographic (TLC) mobility, electron-capture gas-chromatographic (EC-GC) retention time, and mass spectrum relative to authentic N-desmethyldiazepam. Plasma levels of N-desmethyldiazepam in subjects receiving both single and chronic doses of chlordiazepoxide were determined by an EC-GC method with a limit of sensitivity of 10 ng/ml using 2-ml samples and by a radioimmunoassay procedure which had a limit of sensitivity of 20 ng/ml using a 0.1-ml sample. Both assay methods gave good agreement for the levels of N-desmethyldiazepam. In subjects receiving a single 30-mg oral or intravenous dose of chlordiazepoxide, measurable levels of N-desmethyldiazepam in plasma (10 to 60 ng/ml) were obtained 24 to 72 hr after administration. In 5 subjects receiving 10 mg of chlordiazepoxide three times a day, steady-state levels of N-desmethyldiazepam in plasma were reached after about 1 wk of administration. The mean maximum and minimum steady-state levels of N-desmethyldiazepam were 260 and 220 ng/ml of plasma, respectively. Similar steady-state levels were observed on treatment with 30 mg of chlordiazepoxide over 24 hr.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 788991     DOI: 10.1002/cpt1976204450

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  6 in total

1.  Physiological and psychological effects of clorazepate in man.

Authors:  M H Lader; S Curry; W J Baker
Journal:  Br J Clin Pharmacol       Date:  1980-01       Impact factor: 4.335

2.  Pharmacokinetic and biopharmaceutic profile of chlordiazepoxide HC1 in healthy subjects: multiple-dose oral administration.

Authors:  H G Boxenbaum; K A Geitner; M L Jack; W R Dixon; S A Kaplan
Journal:  J Pharmacokinet Biopharm       Date:  1977-02

3.  Clinical pharmacokinetics of chlordiazepoxide in patients with alcoholic hepatitis.

Authors:  D D Morgan; J D Robinson; C L Mendenhall
Journal:  Eur J Clin Pharmacol       Date:  1981-03       Impact factor: 2.953

4.  The application of HPLC to the determination of some 1,4 benzodiazepines and their metabolites in plasma.

Authors:  G G Skellern; J Meier; B I Knight; B Whiting
Journal:  Br J Clin Pharmacol       Date:  1978-06       Impact factor: 4.335

Review 5.  Clinical pharmacokinetics of chlordiazepoxide.

Authors:  D J Greenblatt; R I Shader; S M MacLeod; E M Sellers
Journal:  Clin Pharmacokinet       Date:  1978 Sep-Oct       Impact factor: 6.447

6.  Elimination kinetics of desmethyldiazepam in two young and two elderly subjects.

Authors:  G M Pacifici; L Cuoci; G F Placidi; P Fornaro; R Gomeni
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1982 Jan-Mar       Impact factor: 2.441

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.